Fasinumab
Fasinumab is a human monoclonal antibody designed for the treatment of pain.[1] Fasinumab for acute sciatic pain[2]
This drug was developed by Regeneron Pharmaceuticals.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Fasinumab, American Medical Association.
- ↑ http://www.dovepress.com/fasinumab-regn475-an-antinerve-growth-factor-monoclonal-antibody-for-t-peer-reviewed-article-JPR
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems |
|---|
| | Bone ("-os-", "-s(o)-") | Human ("-osu-") | |
|---|
| Humanized ("-sozu-") | |
|---|
|
|---|
| | Musculoskeletal ("-mul-") | |
|---|
| | Circulatory ("-c(i[r])-") | Human ("-ciru-") | |
|---|
| Mouse ("-ciro-") | |
|---|
| Chimeric ("-cixi-") | |
|---|
| | |
|---|
|
|---|
| | Neurologic ("-ne(u)(r)-") | Human ("-neru-") | |
|---|
| Humanized ("-nezu-"/"-neuzu-") | |
|---|
|
|---|
| | Angiogenesis inhibitor ("-anibi-") | |
|---|
| |
|